scout
Commentary|Videos|February 4, 2025

The Phase 3 inMIND Trial: Tafasitamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss key updates in the follicular lymphoma field following the 2024 ASH Annual Meeting

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for tafasitamab in relapsed/refractory follicular lymphoma.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME